<DOC>
	<DOCNO>NCT01722292</DOCNO>
	<brief_summary>The purpose study find recommended dose LY2940680 safely give combination etoposide carboplatin follow LY2940680 alone participants extensive-disease small cell lung cancer . The study also compare progression-free survival participant administer etoposide , carboplatin LY2940680 follow LY2940680 alone versus etoposide , carboplatin , placebo follow placebo alone .</brief_summary>
	<brief_title>A Study LY2940680 Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histological cytological diagnosis Small Cell Lung Cancer ( SCLC ) , include malignant pleural effusion extensive stage per International Staging System Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) performance status schedule No prior systemic chemotherapy , immunotherapy , biological therapy SCLC Prior radiation therapy allow &lt; 25 % bone marrow . Participants receive prior radiation whole pelvis chest treatment SCLC eligible At least 1 unidimensionally measurable lesion meeting Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Adequate organ function include follow : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ≥1.5 x 10^9/ liter ( L ) , platelets ≥100 x 10^9/L , hemoglobin ≥9 grams/deciliter ( g/dL ) Hepatic : bilirubin ≤1.5 time upper limit normal ( ULN ) , alkaline phosphatase ( AP ) , Serum alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) ≤3.0 x ULN ( AP , AST , ALT ≤5 x ULN acceptable liver tumor involvement ) Renal : calculated creatinine clearance ( CrCl ) ≥50 milliliter per minute ( mL/min ) base standard Cockcroft Gault formula Estimated life expectancy least 12 week For woman : Must surgically sterile , postmenopausal , compliant medically approve contraceptive regimen 6 month treatment period ; must negative serum pregnancy test within 7 day study enrollment . For men : Must surgically sterile compliant contraceptive regimen 6 month treatment period Availability tumor tissue sample Able swallow capsule Currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Have previously participate study involve LY2940680 Have previously receive treatment carboplatin etoposide Have mixed histological diagnosis SCLC NonSmall Cell Lung Cancer ( NSCLC ) Have serious concomitant systemic disorder , opinion investigator , would compromise participant 's ability adhere protocol Have active infection [ ≥38.5 degrees Celsius and/or receive Intravenous ( IV ) antibiotic therapy ] Have serious cardiac condition Have prior malignancy SCLC , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence . Participants history nonmetastatic prostate cancer , include biochemical relapse , eligible even diagnose less 5 year previously Symptomatic central nervous system ( CNS ) metastases asymptomatic CNS metastasis require concurrent corticosteroid therapy . Treated stable CNS metastasis allow ; participant must stable radiotherapy ≥2 week corticosteroid ≥1 week Presence clinically significant thirdspace fluid collection control prior study entry Significant weight loss ( , ≥10 % ) 6week period prior study entry Concurrent administration antitumor therapy . An exception make nonmetastatic prostate cancer participant continue androgen blockade therapy breast cancer participant continue adjuvant antiestrogen therapy ( example , aromatase inhibitor ) Females breastfeed Have correct QT interval ( QTc ) &gt; 470 millisecond ( msec ) screen electrocardiogram ( ECG ) Have receive medication strong inhibitor Cytochrome P450 3A4 ( CYP3A4 ) within 7 day prior receive study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>